Preliminary Results from a Phase Ib Study Exploring MDM2 Inhibitor Siremadlin (HDM201) in Combination with B-Cell Lymphoma-2 (BCL-2) Inhibitor Venetoclax in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (HR-MDS)

被引：5
|
作者：
Wei, Andrew H. [1 ,2 ]
Breccia, Massimo [3 ]
Ooi, Melissa [4 ]
Romero, Maria Teresa Cedena [5 ]
Ciceri, Fabio [6 ]
Erba, Harry P. [7 ]
Gaur, Anil [8 ]
Sechaud, Romain [9 ]
Halilovic, Ensar [10 ]
Kuenzle, Brigitte [9 ]
Fabre, Claire [9 ]
Porkka, Kimmo [11 ]
机构：
[1] Alfred Hosp, Melbourne, Vic, Australia
[2] Monash Univ, Melbourne, Vic, Australia
[3] Sapienza Univ Rome, Rome, Italy
[4] Natl Univ Canc Inst, Singapore, Singapore
[5] Hosp Univ 12 Octubre, Inst Invest Sanitaria Imas12, Madrid, Spain
[6] IRCCS Osped San Raffaele, Milan, Italy
[7] Duke Univ, Blood Canc Ctr, Hematol Malignancies Clin, Durham, NC USA
[8] Novartis Healthcare Pvt Ltd, Hyderabad, India
[9] Novartis Pharmaceut, Basel, Switzerland
[10] Novartis Inst BioMed Res, Cambridge, MA USA
[11] Univ Helsinki, Cent Hosp, Ctr Canc, Helsinki, Finland
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-144650
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1283
引用
收藏
页数：4
相关论文
共 21 条
  • [1] Preliminary Results from a Phase Ib Study Evaluating BCL-2 Inhibitor Venetoclax in Combination with MEK Inhibitor Cobimetinib or MDM2 Inhibitor Idasanutlin in Patients with Relapsed or Refractory (R/R) AML
    Daver, Naval
    Pollyea, Daniel A.
    Yee, Karen W. L.
    Fenaux, Pierre
    Brandwein, Joseph M.
    Vey, Norbert
    Martinelli, Giovanni
    Kelly, Kevin R.
    Roboz, Gail J.
    Garcia, Jacqueline S.
    Pigneux, Arnaud
    Kshirsagar, Smita
    Dail, Monique
    Wang, Jue
    Mobasher, Mehrdad
    Chen, Lin-Chi
    Hong, Wan-Jen
    Konopleva, Marina
    Andreeff, Michael
    BLOOD, 2017, 130
  • [2] PRELIMINARY RESULTS FROM A PHASE 1 STUDY EXAMINING THE NOVEL BCL-2 INHIBITOR S55746/BCL201 AS SINGLE AGENT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OR HIGH RISK MYELODYSPLASTIC SYNDROME
    Wei, A.
    Bajel, A.
    Boissel, N.
    Kloos, I.
    Delifer, C.
    Banquet, S.
    Thomas, X.
    Vey, N.
    HAEMATOLOGICA, 2017, 102 : 373 - 373
  • [3] Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study
    Brunner, Andrew M.
    Esteve, Jordi
    Porkka, Kimmo
    Knapper, Steve
    Vey, Norbert
    Scholl, Sebastian
    Garcia-Manero, Guillermo
    Wermke, Martin
    Janssen, Jeroen
    Traer, Elie
    Loo, Sun
    Narayan, Rupa
    Tovar, Natalia
    Kontro, Mika
    Ottmann, Oliver
    Naidu, Purushotham
    Kurtulus, Sema
    Makofske, Jessica
    Liao, Serena
    Mohammed, Anisa
    Sabatos-Peyton, Catherine A.
    Rinne, Mikael L.
    Borate, Uma
    Wei, Andrew H.
    BLOOD, 2020, 136
  • [4] Preliminary Safety and Efficacy Of BGB-11417, a Potent and Selective B-Cell Lymphoma 2 (BCL2) Inhibitor, in Patients (Pts) with Acute Myeloid Leukemia (AML)
    Shortt, Jake
    Platzbecker, Uwe
    Tan, Shuh Ying
    Cannell, Paul
    Ng, Teng Fong
    Fong, Chun Yew
    Ramanathan, Sundra
    Rajagopal, Rajeev
    Leitch, Sophie
    Gasiorowski, Robin
    Grove, Carolyn
    Lenton, Douglas
    Tan, Peter
    Dinardo, Courtney
    Ling, Ming Tat
    Cheng, Si
    Liu, Yuan
    Co, Melannie
    Chan, Wai Y.
    Simpson, David
    Wei, Andrew H.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 144 - 144
  • [5] PHASE IB STUDY OF PF-04449913, A HEDGEHOG (HH) INHIBITOR, IN COMBINATION WITH LOW-DOSE CYTARABINE OR INTENSIVE CHEMOTHERAPY, IN ACUTE MYELOID LEUKEMIA (AML) OR HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)
    Cortes, J.
    O'Connell, A.
    Shaik, M. N.
    Cesari, R.
    Abbattista, A.
    Woolfson, A.
    Pollyea, D.
    Savona, M.
    HAEMATOLOGICA, 2014, 99 : 33 - 33
  • [6] Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating drugs (HMAs) in patients with very high or high risk myelodysplastic syndrome (vHR/HR-MDS) and acute myeloid leukemia (AML): final analysis after a phase Ib study
    Brunner, A.
    Porkka, K.
    Knapper, S.
    Traer, E.
    Scholl, S.
    Garcia-Manero, G.
    Vey, N.
    Wermke, M.
    Janssen, J.
    Narayan, R.
    Loo, S.
    Tovar, N.
    Kontro, M.
    Naidu, P.
    Pelletier, M.
    Steensma, D.
    Lewandowski, A.
    Zhang, N.
    Mohammed, A.
    Borate, U.
    Wei, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 35 - 36
  • [7] Preliminary Results from the Phase II Study of the IDH2-Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS)
    Richard-Carpentier, Guillaume
    DeZern, Amy E.
    Takahashi, Koichi
    Konopleva, Marina Y.
    Loghavi, Sanam
    Masarova, Lucia
    Alvarado, Yesid
    Ravandi, Farhad
    Bravo, Guillermo Montalban
    Naqvi, Kiran
    Sasaki, Koji
    Delumpa, Ricardo
    Kwari, Monica
    Sekeres, Mikkael A.
    Nazha, Aziz
    Roboz, Gail J.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    DiNardo, Courtney D.
    BLOOD, 2019, 134
  • [8] Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
    Assi, Rita
    Kantarjian, Hagop M.
    Daver, Naval G.
    Garcia-Manero, Guillermo
    Benton, Christopher B.
    Thompson, Philip A.
    Borthakur, Gautam
    Kadia, Tapan M.
    Alvarado, Yesid
    Jabbour, Elias J.
    Konopleva, Marina Y.
    Takahashi, Koichi
    Kornblau, Steven M.
    DiNardo, Courtney D.
    Estrov, Zeev E.
    Flores, Wilmer
    Basu, Sreyashi
    Allison, James P.
    Sharma, Padmanee
    Pierce, Sherry A.
    Pike, Allison
    Cortes, Jorge E.
    Ravandi, Farhad
    BLOOD, 2018, 132
  • [9] A phase II study of venetoclax (VEN) in combination with 10-day decitabine (DEC) in older/unfit pts with newly diagnosed (ND) or pts with relapsed/refractory (R/R) acute myeloid leukemia (AML), or high-risk myelodysplastic syndrome (HR-MDS).
    Swaminathan, Mahesh
    Dinardo, Courtney Denton
    Maiti, Abhishek
    Pemmaraju, Naveen
    Ohanian, Maro
    Daver, Naval Guastad
    Garcia-Manero, Guillermo
    Issa, Ghayas C.
    Borthakur, Gautam
    Ravandi-Kashani, Farhad
    Montalban-Bravo, Guillermo
    Kadia, Tapan M.
    Valero, Yesid Alvarado
    Jabbour, Elias
    Short, Nicholas James
    Wierda, William G.
    Jain, Nitin
    Kornblau, Steven Mitchell
    Kantarjian, Hagop M.
    Konopleva, Marina
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] A Phase 1-2 Study of a Farnesyltransferase Inhibitor, Tipifarnib, Combined With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
    Jabbour, Elias
    Kantarjian, Hagop
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Estrov, Zeev
    Verstovsek, Srdan
    O'Brien, Susan
    Faderl, Stefan
    Thomas, Deborah A.
    Wright, John J.
    Cortes, Jorge
    CANCER, 2011, 117 (06) : 1236 - 1244
123